AKT1 and Parkinson disease: Thus, medications like adropin that target the dopaminergic system via Akt activation or those with the potential to increase the phosphorylated Akt have neuroprotective characteristics in PD (Ries et al., 2006; Burke, 2007; Levy et al., 2009; Timmons et al., 2009).